Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Evoke Pharma (EVOK)

Evoke Pharma (EVOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,434
  • Shares Outstanding, K 1,486
  • Annual Sales, $ 5,180 K
  • Annual Income, $ -7,790 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 0.36
  • Price/Sales 1.29
  • Price/Cash Flow N/A
  • Price/Book 0.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.03 +7.44%
on 11/13/24
12.32 -64.85%
on 10/28/24
-1.07 (-19.81%)
since 10/22/24
3-Month
3.54 +22.32%
on 09/05/24
12.32 -64.85%
on 10/28/24
-0.10 (-2.26%)
since 08/22/24
52-Week
3.54 +22.32%
on 09/05/24
17.40 -75.11%
on 12/05/23
-10.72 (-71.24%)
since 11/22/23

Most Recent Stories

More News
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

EVOK : 4.33 (-3.78%)
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®

EVOK : 4.33 (-3.78%)
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

EVOK : 4.33 (-3.78%)
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

EVOK : 4.33 (-3.78%)
Evoke Pharma Reports Second Quarter 2022 Financial Results

Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11%...

EVOK : 4.33 (-3.78%)
Evoke Pharma to Report Second Quarter Results on August 10, 2022

SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...

EVOK : 4.33 (-3.78%)
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)

Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7...

EVOK : 4.33 (-3.78%)
Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...

EVOK : 4.33 (-3.78%)
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...

EVOK : 4.33 (-3.78%)
Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported

Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients...

EVOK : 4.33 (-3.78%)

Business Summary

Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke...

See More

Key Turning Points

3rd Resistance Point 4.78
2nd Resistance Point 4.69
1st Resistance Point 4.51
Last Price 4.33
1st Support Level 4.24
2nd Support Level 4.15
3rd Support Level 3.97

See More

52-Week High 17.40
Fibonacci 61.8% 12.11
Fibonacci 50% 10.47
Fibonacci 38.2% 8.83
Last Price 4.33
52-Week Low 3.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar